Go to menu Go to contents Go to footer

Samyang Corpotation

Samyang Corp. News

samyang_news
Samyang Biopharm USA Appoints Ryu Eun-ju as Its New President Print
Writer administrator Hits 2463 2022.02.11

- Expertise in new global pharmaceutical businesses and global marketing, such as global clinical trial management, licensing and global marketing

- Has key capabilities in establishing and commercializing global strategies for anticancer drugs and treatment for rare diseases

- “Plan to lay foundation for the growth in the long run by securing new R&D pipelines and expanding business portfolios”

 

Ryu Eun-ju, New President of Samyang Biopharm USA

 

Samyang Biopharm USA, a global biopharmaceutical corporation under Samyang Group, announced on February 10 that Ryu Eun-ju has been newly appointed as its President.

 

Ryu brings more than 30 years of expertise in establishing new pharmaceutical business and marketing strategies such as global clinical trial management and licensing for global pharmaceutical companies.

 

She graduated from the College of Pharmacy at Ewha Womans University and earned her master’s degree in Clinical Pharmacy at Sookmyung Women’s University and MBA degree at New York University in the U.S. Ryu was the head of the Oncology & Specialty Business Unit at Pfizer Pharmaceuticals Korea, and has worked at the headquarters in the U.S. since 2006, showing expertise in various positions, such as Marketing Director of Japan and Asia, Portfolio Acquisition Director and Global Marketing Director. She also led the development of global clinic trials and new businesses in Bayer Korea and other medical companies in the U.S. Ryu was awarded by the Minister of Health and Welfare for contributing to the cooperation and development of the U.S.-Korea pharmaceutical bio-industries.

 

Lee Young-Joon, head of the Biopharmaceuticals Division, said, “Ryu has key capabilities in establishing and commercializing global strategies for anticancer drugs and treatment for rare diseases. She will contribute to Samyang Biopharm USA taking the next big step forward with her capabilities and experiences.”

 

Ryu commented, “I am happy to be the new President of Samyang Biopharm USA, striving to contribute to improving the quality of patients’ lives by developing innovative anticancer drugs. I plan to lay the foundation for the growth of Samyang Biopharm USA in the long run by securing new R&D pipelines and expanding business portfolios.”

 

Samyang Biopharm USA is an overseas corporation of Samyang Holdings established in the center of the global bio industry at Kendall Square, Boston in August 2018 with the goal of developing innovative oncology drugs and rare disease treatments. Samyang Biopharm USA intends to increase the speed and success rate of biopharmaceutical development by conducting global clinical trials of new oncology drug candidates studied by the Samyang Holdings Biopharmaceuticals Division in Korea through the implementation of the open innovation strategy that aims to introduce and develop new biopharmaceutical technologies and materials at an early stage by making the most out of its position. Currently, the company continues to search for new drug candidates targeting immunotherapy and rare disease treatments.

 

 

Prev Samyang Holdings Biopharmaceuticals Division Acquires Sales Approval in Japan for Its Anti-Cancer Drug Azacitidine Injection 2022.03.17
Next Samyang Packaging Prioritizes ESG by Expanding Its Plastic Recycling Business 2022.01.25